''Cannery Row in Monterey in California is a poem, a stink, a grating noise, a quality of light, a tone, a habit, a nostalgia, a dream.(how can this) be set down alive? When you collect marine animals there are certain flat worms so delicate that they are almost impossible to capture whole, for they break and tatter under the touch. You must let them ooze and crawl of their own will onto a knife blade and then lift them gently into your bottle of seawater.'' 1 So, that's what I will do: let the science from my laboratory ''ooze and crawl of [its] own will'' across time as my ideas were developed, tested, and then refined. It is possible that some might contest my narrative, but it is my eyewitness account. From the beginning, the work from my laboratory had three cardinal features: it involved both statistical and experimental approaches, both familybased and population-based studies, and an evolutionary perspective. But, to understand how my work developed, I have to start at the beginning.
I was born and grew up in Calcutta, a much maligned and blighted city in the Western imagination but one with a long tradition of excellence, independence, and dissent. Founded in 1690, it is an old city and has been continually exposed to foreign cultures, starting with the Mughals and then continuing with a variety of European influences. Calcutta was the nucleus of the Bengal renaissance and was once the center of Indian education, science, culture, and politics. Yes, I said ''once'': a reminder that current success is ephemeral. It is a city where Photo courtesy of ASHG. diversity is its DNA and its residents are interested in the whole spectrum of the arts and humanities, science, and politics. It is this city's crucible that exposed me to more possibilities than my mind could imagine. 7 I demonstrated that it is inherited in a nearrecessive manner and was surprised at its estimated high allele frequency. The trait is common around the world, and I was astounded (and still remain so) as to why such a benign (useless?) trait is so variable. I thought perhaps it was in allelic association with some beneficial mutation, but that would require approaches that were not yet available and also unthinkable. Second, November 1978 was a big month for me. Most importantly, I got married to my wife, Shukti. But, the very same month, I came across Kan and Dozy's ground-breaking paper, 8 which showed three successes: identification of the first human DNA polymorphism, its location in noncoding DNA, and its association (LD) with the sickle mutation! This study was a home run for me and opened many doors for me where none existed. As of today, it is the paper that set our field on a different trajectory. The finding of an association between a disease mutation and a specific marker, even outside a gene of interest, was remarkable given that it immediately suggested a way of mapping and identifying specific mutations: in reverse. However, the scale of such mapping in humans was unknown. I knew that in Drosophila large regions could be in allelic association, but usually that was from suppressed recombination within common chromosomal inversions; the human genome was not known to harbor these and was 30 times larger. To begin this LD-based reverse genetics, I required a test case. The globins were one of the most attractive genomic regions to tackle because their mutations were known, their genes had been recently cloned and mapped to individual chromosomes, and their physical arrangements had been elucidated. A chance encounter-my pursuit of data to understand molecular patterns of LD and Haig Kazazian and Stylianos Antonarakis's search to identify the molecular basis of b-thalassemias-led to our collaboration on understanding the patterns of diversity and association in the b-globin cluster. These studies, with my graduate student Ken Buetow, were the first quantitative studies of LD in the human to give us the scale of population recombination, demonstrate the existence of haplotype ''frameworks'' (now called blocks), and show that associations can dissipate over very short distances. We inferred that meiotic recombination is nonuniform in the human genome and mapped the location of a putative recombination hotspot adjacent to the b-globin-encoding gene. 9 Although these ideas and observations were contested and very controversial when we published them in 1984, they have stood the test of time and are now commonplace, no doubt because of Mark Daly's subsequent studies on an interleukin cluster. 10 The research I am not recounting, because it's not my own, is Haig and Stylianos's great success in using the b-globin frameworks for identifying a diverse set of molecular thalassemia mutations; Haig received the Allan Award in 2008 partly for these successes.
11 I wanted to do the same but in a situation where the gene for a phenotype was unknown. In the 1980s, positional cloning had come into its own, but all of the successes, except Stuart Orkin and Lou Kunkel's work on chronic granulomatous disease, 12 were based on a chromosomal lesion interrupting the coding sequence of the relevant gene. LD mapping suggested a new approach provided that the mutant allele was common. The perfect candidate was cystic fibrosis (CF) given that its high incidence defied the mutation-selection balance and suggested a single polymorphic (2%) mutant allele maintained through overdominant selection. In 1985, at these meetings, Lap-Chee Tsui presented the first DNA marker linked to CF. I met Lap-Chee at these meetings, and we personally hit it off. This started my laboratory's work, specifically by graduate student Tara Cox Matise, on LD mapping in CF. Importantly, LD mapping played a very critical role in the positional identification of CFTR in 1989, and our elucidation of haplotypes in CF-affected families uncovered a rich haplotype diversity, of which the most frequent one harbored the now-famous common mutant DF508. 13 These studies would have been impossible without Lap-Chee's postdoctoral fellow BatSheva Kerem, who painstakingly generated tens of highfrequency RFLP markers mapped relative to one another (an LD map). It is not surprising then that the CF studies, conducted in an outbred rather than isolated population, imprinted upon me the necessity of a high-frequency-polymorphism map across the human genome for disease mapping; I was not alone in this realization, given that Neil Risch, Eric Lander, and Francis Collins had individually proposed the same. [14] [15] [16] The first of these maps was created by Eric
Lander's group. 17 However, it took completion of the human genome sequence for a group of us-largely Francis Collins, Eric Lander, David Altshuler, David Bentley, Peter Donnelly and myself-to eventually champion, participate, and create the high-resolution maps of the HapMap Project for common variants. 18, 19 Even prior to these studies, it was clear that having a technology for screening human genes directly for sequence variants, particularly candidates for a given disorder, would be immensely helpful. One of my graduate students, Marc Halushka, worked extensively with Jian-Bing Fan at Affymetrix to complete such a study for candidate hypertension genes by using the then novel array technology. 20 These studies, and a near-identical one from Eric Lander's laboratory, 21 were published back to back in 1999 and showed how diverse some human proteins are and that purifying selection on nonsynonymous alterations is widespread, ideas now commonplace. Consequently, by 2007, a near-complete common-variant map including dense coverage of genes was freely available through the HapMap project, a feature that has changed complex disease mapping and its biology forever. Indeed, with the completion of the 1000 Genomes Project, 22, 23 which I also championed and participated in, I
cannot imagine a nongenomic genetics world. Let me now turn to another of my laboratory's parallel developments that intellectually merged with the studies I have described so far. Although my statistical training and interests allowed me to be useful to others in genetic studies of Mendelian disorders, I was far more interested in understanding why some disorders are complex. R.A. Fisher's so-called synthesis in 1918 of the BiometricalMendelian debate on the nature of genetic inheritance was an artifice: it was a correct statistical description of complex inheritance, but not a molecular one. 24 So, it was quite lucky that I came across an ideal opportunity: I was asked to review the 1986 Master's thesis of a University of Pittsburgh genetic-counseling student who had studied the genetic epidemiology of HSCR. 25 My simple reading of the literature suggested that this disorder might be amenable to genetic dissection using the evolving genetic maps and positional cloning methods-perhaps not in 1986, but soon. What sealed the deal was the conversation between the two senior committee members: the geneticist lamenting that ''we might not ever understand the underlying genes'' and the pediatric surgeon arguing that ''I am no geneticist, but all I know is that I am repairing the children of kids I repaired 25 years ago.that must count for something.'' In my mind, that counted for a lot! HSCR (or congenital aganglionosis) is a neurodevelopmental defect of the enteric nervous system and is characterized by a lack of nerve supply in segments of the gut, leading to an absence of peristalsis and a functional intestinal blockage. 26 It is lethal if not surgically resected, and today, rates of postoperative complication can be as high as 30%. It is considered a multifactorial disorder and is fairly frequent at 1 in 5,000 live births in newborns of European ancestry but is twice as common in Asian infants. HSCR also shows a curious sex bias in that four times as many males as females are affected. The available genetic data in 1986 showed some evidence of discrete genetic loci given that numerous syndromic associations, pedigrees in which HSCR segregated in a near-dominant fashion, and recessive mouse models were already known. 26 To settle the issue, one of my MD-PhD students, Judy Badner, performed statistical analysis of both the extant published data and families we collected through the Children's Hospital of Pittsburgh to show four remarkable features: its very high heritability, high prevalence of associated anomalies, inverse relationship between the extent of aganglionosis and sex ratio, and predicted genetic etiologies in almost all cases! 27 Moreover, nearly 15% of our severe long-segment cases were compatible with incomplete dominance and were thus amenable to genetic mapping using the just discovered microsatellite markers.
In and Giovanni Romeo 31 in Genoa identified deleterious mutations in RET, encoding a receptor tyrosine kinase. We followed with a report on diverse loss-of-function mutations throughout the length of RET in all forms of HSCR but found fewer coding mutations (at lower penetrance) than others did. 32 Nevertheless, we failed to find any RET variants in the vast majority of the families we studied. In parallel, Erik Puffenberger, another graduate student, followed up on an extensive Old Order Mennonite kindred in which HSCR segregated in an apparently ''recessive'' form by performing a genome-wide linkage study using identity-by-descent sharing to implicate a locus on chromosome 13q. 33 Subsequently, we engaged in an exciting collaboration with Masashi Yanagisawa at University of Texas Southwestern to implicate a common (15%) hypomorphic missense substitution in the G-protein-coupled receptor EDNRB. 34 Interestingly, this variant showed different degrees of penetrance in all three genotypes and also showed interaction with a common RET haplotype. In quick succession, on the basis of our own studies and the published biochemistry, we also demonstrated substitutions in these two receptors' ligands (namely GDNF 35 and EDN3 36 ) and, in collaboration with Bill Pavan 37 at the National Institutes of Health, in relevant transcription factor SOX10. Mutations in SOX10 were identified by Michele Goosens' group 38 the previous year as a cause of Shah-Waardenburg syndrome, one of the HSCR syndromes. However, the mystery of the reduced penetrance of all of the mutations identified still remained. We hypothesized that full penetrance came about from the joint action of both RET and EDNRB mutations. Given the commonality of the EDNRB variant in Mennonites, in 2002, Minerva Carrasquillo, then a graduate student in my laboratory, performed one of the first microsatellite-marker-based genome-wide association studies in the genetically isolated Old Order Mennonites to demonstrate that strong epistasis between RET and EDNRB mutations leads to higher penetrance. 39 This work would have been less significant were it not buttressed in this 39 and subsequent work (by Andy
McCallion, then a postdoctoral fellow in my laboratory)
showing that these epistatic interactions could be fully recapitulated and lead to sex-biased expression of aganglionosis in mice. 40 Honestly, we were quite pleased because in a matter of 10 years, we had gone from a statistical description of HSCR inheritance to knowing some of its molecular details with precision and how the complex phenotype was synthesized. We postulated a crude theory that HSCR resulted from disrupted biochemical interactions either within enteric neuroblasts or between neuroblasts and the growth-factor-secreting cells of the gut mesenchyme. These studies automatically led to a search for multiple rare mutations within individual patients, and these we and others described. A persistent feature of all of these studies was the primacy of RET mutations in our patients. Our idea at that time was that HSCR patients had one primary RET mutation and at least one other in a RET-dependent modifier. Stacey Bolk Gabriel, not the confident person of today but then a quiet graduate student in my laboratory, performed two of these screens to map such modifiers. 41, 42 One of these screens, in short-segment HSCR, was performed with Remi Salomon, visiting from Stan Lyonnet's laboratory in Paris, and clearly demonstrated the primacy of the RET effect and the existence of at least two polymorphic modifier loci; interestingly, these three loci recapitulated both the HSCR incidence and recurrence risk. 42 What was to come was even more surprising. Over time, we found fewer and fewer RET coding mutations; I reasoned that our early data were biased upward given that we had primarily collected multiplex families for linkage studies. I hypothesized that if RET was involved in nearly every HSCR patient and coding mutations were relatively rare, then the remaining mutations must be in a neighboring gene or a noncoding functional element. In 2005, in an elegant series of experiments, my postdoctoral fellow Eileen Emison and the newly independent Andy McCallion, in collaboration with Eric Green at the National Human Genome Research Institute and his postdoctoral fellow Matthew Portnoy, performed old-fashioned sequencing of retrieved bacterial artificial clones containing RET from 12 vertebrates and used comparative sequence analysis to identify conserved noncoding elements. 43 Betsy
Grice, a graduate student with Andy McCallion, did functional analyses of 18 elements to identify numerous potential RET enhancers, including those acting in gut development in the mouse. 44 Our data on sequencing these enhancers in HSCR patients quickly identified a highly polymorphic variant, called RETþ3, in the most potent gut enhancer within intron 1 of RET as the causal site. to publish a large study that clearly demonstrated that this enhancer variant has unique properties and explains many features of HSCR's complex inheritance: it had the highest frequency in the commonest and least severe cases (simplex males with short-segment disease) and the lowest frequency in the rarest and most severe cases (multiplex females with long-segment disease); interestingly, coding mutations had the precise opposite relationship. 45 Indeed, the enhancer genotypes varied in risk by 200-fold. We also demonstrated by functional analysis that these effects arose from the abrogation of SOX10 binding at the enhancer. 45 Our recent forays into the effects of RET enhancers are even more intriguing. In unpublished work (presented at this meeting) by two current postdoctoral fellows, Sumantra Chatterjee and Ashish Kapoor, we show that HSCR risk is affected by two interacting noncoding elements each imparting differential genetic risk. 46 The second element identified by a genome-wide association study is 125 kb upstream of the transcription start site and is the predicted binding site for a retinoic acid receptor, binding of which is attenuated in the risk variant. We need to prove this hypothesis functionally but believe in its likelihood given that independent work by Robert Heuckeroth at Washington University in St. Louis has shown that vitamin A deficiency in a Ret heterozygote mouse leads to aganglionosis. 47 Therefore, RET genetic risk is affected by at least two ''shadow'' enhancers. These two cis-regulatory elements, which we show in collaboration with Len Pennacchio and Eddy Rubin, are both active in the gut and neurons, act at slightly different developmental time points, and use the two different transcription factors SOX10 and RARA. This is most likely the first description in humans of complex genetic disease arising from two interacting enhancers that, in the wild-type, provide exquisite control over enteric nervous system development.
To uncover all of HSCR's associated genes, in the past year, we have collaborated with Stacey Gabriel of the Broad Institute of Harvard and MIT in Cambridge to complete initial analysis of the exome sequences of a diverse group of 189 HSCR probands. The chief protagonists of this experiment in my laboratory have been two graduate students, K.D. Nguyen and Tychele Turner, who have had considerable help from Courtney Berrios, my genetics counselor, and Albee Ling. Compared to controls, HSCR genomes show a~1.5% excess of highly deleterious variants. To identify these specifically, we sought all genes with more deleterious sequence variants than dictated by chance and further narrowed this set to those with three or more deleterious variants. We were astonished to net 363 genes! Is this list credible? We strongly believe so given that both RET and EDNRB were identified, as were mutations in six other known HSCR-associated genes. Importantly, these 363 genes are highly enriched with those expressed in the embryonic gut, as assessed by our RNA-sequencing studies in mice at embryonic days 10.5 and 14.5 (over which time the gut and enteric nervous system develop) and human induced-pluripotent-stem-cell-derived neural crest cells. In total, 225 of these genes are expressed in the gut, and the functional categories enriched in this set are genes affecting synaptogenesis, cytoskeletal architecture, and the extracellular matrix. We also have begun analyzing these exome sequences for copy-number variants (CNVs) with Nik Krumm and Evan Eichler at the University of Washington, Seattle. 48 A further surprise is that HSCR patients have an excess of recurrent CNVs already known to be associated with other neurodevelopmental disorders, such as autism and epilepsy. In other words, these recurrent CNVs might predispose to a broad neuronal dysfunction whose specificity is produced when they reside in a genome with other genes mutated in HSCR. All of these are recent results that require validation, confirmation, and peer review. I wanted to share them with you to demonstrate that even a rare disease like HSCR is the result of tens, if not hundreds, of genes and has many valuable lessons to teach us. I will argue that we are just beginning to ''understand'' this complex genetic defect. But, before we do so, are any of the 225 gut-expressed genes with deleterious variants true? We have begun the painstaking work of individually knocking down their function in zebrafish embryos, an excellent model for studying the migration of enteric neurons, to assess their phenotype. The first class we have focused on is a set of genes likely affecting neuronal ubiquitylation by showing that loss of function of UBR4, which encodes an E3 ubiquitin ligase, clearly affects normal ganglionosis in zebrafish and demonstrates strong epistasis with RET.
So, what have we learned? We now know the identity of the many genes that are mutant in HSCR and are beginning to understand how they bring about their effects. Enteric nervous system development is highly dependent on a group of early transcription factors, such as PAX3 and SOX10, and two key signaling molecules, RET and EDNRB. Normal development requires passage through this rate-limiting developmental step, which is why deleterious coding variants in these genes are associated with severe disease. Weaker mutations, such as the enhancer alleles I spoke of, might allow passage through this step, which is why less severe and common forms of HSCR occur from the joint action of these weaker deleterious alleles with additional mutations in subsequent developmental processes, such as in the formation of neuromuscular junctions or in neuronal activity per se. Quite importantly, HSCR is not exclusively a neuronal disease given that mutations in genes affecting nonneuronal tissue, such as the extracellular matrix, have now been identified. I have no doubt that human genetics will prove its worth in the subsequent few years to further solve these puzzles.
None of the work I described would have been possible without a strong belief in the awesome power of human genetics, the principles of evolution, and my deep, deep respect for basic and fundamental research. Many years ago, the great biochemist Arthur Kornberg laid down his ten commandments, such as the one on evolution: ''What's true for E. coli is true for elephants; what's not true for E. coli is simply not true.'' 49 He also humorously wrote that Moses, while coming down from the mountain after his meeting with the Almighty, carried down three tablets, one of which broke but contained the most important 11 th commandment: ''Thou shalt respect basic research.'' 49 In these days, when translation of our science is imminent, the need for basic research is even greater, an aspect that I believe is given insufficient support. Let me end with a few more thanks. First, to my parents, now both deceased. They did much more than give me their genomes; they were giants and have bequeathed to my brothers and me their lives as lessons. Second, to my beautiful wife and our two lovely daughters. I thank them for their daily support and love and all that it takes to make our house a home; our lives are sometimes chaotic but always interesting. My wife, Shukti, is a noted cell and molecular biologist of her own accord, and I have been lucky to have learned ''real'' biology from her through osmosis over our 35 years together. Also, thanks to this country and the ASHG, which have given me so many opportunities. However, this has not come without some pain. The life of immigrants, with the absence of our language, culture, and family, is largely an unobserved one to most of you and carries with it a permanent sense of dislocation and loss. Still, it has been a great and worthwhile journey, and I am not about to turn back. I will end by quoting the last paragraph from the last chapter of the book Interpreter of Maladies, written by one of the best short-story writers in the United States, the Bengali American Jhumpa Lahiri. She writes in the ''Third and Final Continent'' of a protagonist, modeled after her father and similar to mine, who left Calcutta to study in England and then at the Massachusetts Institute of Technology in this very city. The year is 1969, and the protagonist rents a room in the home of the 103-year-old Mrs. Croft, who simply cannot believe that man has landed on the moon. It is to this simple beginning on which he reflects:
''In my son's eyes I see the ambition that had first hurled me across the world. In a few years he will graduate and pave his way, alone and unprotected. But I remind myself that he has a father who is still living, a mother who is happy and strong. Whenever he is discouraged, I tell him that if I can survive on three continents, then there is no obstacle he cannot conquer. While the astronauts, heroes forever, spent mere hours on the moon, I have remained in this new world for nearly 30 years. I know that my achievement is quite ordinary. I am not the only man to seek his fortune far from home, and certainly I am not the first. Still, there are times when I am bewildered by each mile I have traveled, each meal I have eaten, each person I have known, each room in which I have slept. As ordinary as it all appears, there are times when it is beyond my imagination. '' 50 
